Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations & Sustainability

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Senior Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

Q2 2021 Results

Fresenius raises Group earnings guidance after very strong Q2

Presentation (PDF)

Highlights

Financial Highlights Q2/21

Sales

€ 9246 m

+8%¹

Q2/20: €8,920 m

Dividend

€ 0.88

+5%

FY/19: €0.84

EBIT²

€ 1030 m

-4%¹

Q2/20: €1,123 m

Employees

312,734

Dec. 31, 2020: 311,269

Net Income^{2, 3}

€ 474 m

+20%¹

Q2/20: €410 m

Earnings per Share^{2, 3}

€ 0.85

+19%¹

Q2/20: €0.74

¹ In constant currency

² Before special items
³ Net income attributable to shareholders of Fresenius SE & Co. KGaA

Interim 2021 results – Video interview with Stephan Sturm (part 2)
Is there anything to reports that Fresenius will be restructured? Why did we pay a record dividend to our shareholders again this year? Where do we stand on sustainability and what does diversity mean to us? Our CEO Stephan Sturm will answer all these questions in the second part of the video interview.
Interim 2021 results – Video interview with Stephan Sturm (part 1)
Last week we presented our interim results for the 2021 business year. We achieved very healthy growth in the first half, despite the pandemic. Yet additional challenging months await us. So how do we go from here? Where do we stand with our efficiency and profitability initiatives? Our CEO Stephan Sturm took on these and other questions in a video interview.

Business Segments
- As assumed, COVID-19 pandemic continued to impact organic growth in dialysis and downstream businesses; patient excess mortality rates significantly reduced
- Negative exchange rate effects continue
- Earnings development impacted by phasing and strong prior-year base, as indicated
- Financial targets for FY 2021 confirmed
Read more (PDF)
Business Segments
- North America performance impacted by COVID-19 and competitive pressure; effects of temporary manufacturing issues receding
- Normalizing demand in Europe driving strong growth over a COVID-impacted base
- Very strong Emerging Markets growth; China with strong performance given more normalized elective treatment activity
- Outlook improved to low single-digit constant currency EBIT percentage growth
Read more (PDF)
Business Segments
- Gradually recovering elective treatments at Helios Germany
- Excellent treatment activity at Helios Spain results in outstanding organic sales and earnings growth over a weak prior year quarter
- Growth additionally fueled by contributions from acquisitions in Germany and Latin America as well as from the acquired fertility business
- Outlook improved for organic sales and constant currency EBIT growth
Read more (PDF)
Business Segments
- Back to sales and earnings growth despite negative COVID-19 effects
- Project business still marked by COVID-19 but showing clear signs of recovery
- Good performance in the service business; rehabilitation business improving as number of elective surgeries increased
- Excellent order intake
Read more (PDF)

Non-financial and Sustainability Reporting
We are committed to responsible and sustainable management as part of our corporate culture and day-to-day business practice. Only by doing so can we be perceived as a trustworthy and reliable partner in the health care sector.

Read more
Annual Report 2020
- The Fresenius Annual Report 2020 is now available as an online version with enhanced functionality and as a full-content PDF.
- In addition, we introduce our first our first online Sustainability Report, where you will find detailed information on the topic of sustainability at Fresenius.
- Detailed information on the impact of the pandemic on the Fresenius Group can be found in our online Annual Report.
Annual Report (PDF) Online Annual Report
Focus COVID-19
The importance of modern and functional health care for society became particularly clear in 2020 as a result of the COVID-19 pandemic.
Our employees worldwide have tirelessly helped to keep the clinics, dialysis centers, factories and logistics running.

Read more

News

Brief News
Fresenius Kabi enters collaboration to enhance the supply of essential medicines for U.S. Patients

Fresenius Kabi has agreed to collaborate with Phlow Corporation, a public benefit company, to expand access to affordable sterile injectables formulated for U.S. children’s hospitals and to help strengthen the supply chain for U.S.-sourced API and essential medicines. The companies will work together to supply private-labelled products, co-develop and manufacture novel products and make essential medicines rapidly available in the event of a public health emergency.

October 14, 2021Fresenius Kabi

Brief News
2022 DRG inflator for German hospitals set at 2.29%

The price increase for hospital services in Germany has been set at 2.29% for 2022. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

September 15, 2021Fresenius Helios
Brief News
Fresenius Helios publishes second sustainability report

Helios Germany has published its second sustainability report. The 60 pages report "Strong into the future" looks back on the complex challenges of the Corona year 2020 and shows in which areas the pandemic has driven developments for Germany’s largest private hospital operator. Helios Germany has defined four fields for its sustainability strategy: Patients, employees, the environment and compliance. Like the first report in 2019, it was drawn up based on the GRI standards of the Global Reporting Initiative and is now available in German on www.helios-gesundheit.de/nachhaltigkeit. An English version will be published soon.

September 08, 2021Fresenius Helios

Brief News
Biosimilar candidate of Fresenius Kabi shows positive results in two clinical trials

Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11456, a tocilizumab biosimilar candidate, successfully met the primary and secondary endpoints in two consecutively conducted clinical trials. For more information, please visit the Fresenius Kabi website.

September 07, 2021Fresenius Kabi
Brief News
Fresenius Helios divests Volkach clinic

Fresenius Helios sells the clinic in Volkach near Würzburg, Germany, to Remedium Healthcare. A corresponding agreement on the 40-bed hospital also includes the transfer of two associated specialist centers in the region. The transaction is a first result of the ongoing strategic review and optimization of Helios' hospital portfolio. The transaction is expected to close by the first quarter of 2022 at the latest. Both sides have agreed not to disclose financial details.

September 07, 2021Fresenius Helios

Brief News
Helios acquires two hospitals in Kassel, Germany

Helios acquires the DRK (German Red Cross) Kliniken Nordhessen in Kassel with two clinics with a total of 433 beds and an associated outpatient care center (MVZ), which generated sales of around €87 million in 2020. The DRK-Schwesternschaft remains a co-partner. Together with the existing Helios hospital in Warburg, a regional medical cluster shall be formed and expanded over the next few years. The acquisition is expected to be completed in the fourth quarter of 2021. The purchase price is 1 euro and includes the assumption of debts and the securing of liquidity for current operations and for future investments.

September 02, 2021Fresenius Helios
Fresenius raises Group earnings guidance after very strong Q2

July 30, 2021Fresenius

Fresenius signs 2 billion euros syndicated revolving credit facility with a link to sustainability

July 02, 2021Fresenius
Brief News
Fresenius Kabi launches IV Drug in the U.S.

Temsirolimus Injection, a drug used to treat advanced renal cell carcinoma, is now available from Fresenius Kabi in the United States. This is the newest addition to the company’s portfolio of generic IV oncology products - the largest such portfolio in the U.S.

May 21, 2021Fresenius Kabi

Fresenius with good start to 2021 despite ongoing COVID-19 impact

May 06, 2021Fresenius
Fresenius successfully places bonds with a volume of 1.5 billion euros

March 23, 2021Fresenius

Michael Sen to succeed Mats Henriksson as CEO of Fresenius Kabi

March 16, 2021Fresenius Kabi
Brief News
Fresenius Kabi launches IV Drug in the U.S.

Foscarnet Sodium Injection is now available in the United States, expanding the company’s anti-viral portfolio. The drug is used in the treatment of conditions associated with immunocompromised patients.

March 15, 2021Fresenius Kabi

Fresenius achieves 2020 targets and expects healthy business development in 2021 despite ongoing COVID-19 impact

February 23, 2021Fresenius
Fresenius achieves FY/20 guidance demonstrating resilience amid the COVID-19 pandemic – Targets healthy sales growth and at least broadly stable net income year over year in FY/21

February 01, 2021Fresenius

Fresenius Helios acquires fertility services provider Eugin Group

December 21, 2020Fresenius Helios
Brief News
Fresenius improves in climate ranking

Fresenius has once again improved in this year's CDP ranking (formerly "Carbon Disclosure Project"). With a ranking in the second highest category B, Fresenius is one of the leading companies in the health care sector, both in Europe and globally. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 515 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.

December 11, 2020Fresenius

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Acetaminophen injection is now available in the United States in ready-to-administer freeflex^® bags, expanding the company’s anesthesia and analgesia portfolio. The drug is used in the hospital setting for pain management and fever reduction.

December 10, 2020Fresenius Kabi
Brief News
Fresenius Kabi launches its first specialty IV drug in the U.S.

Icatibant injection, an FDA-approved and cost-effective alternative to treat acute attacks of hereditary angioedema in adults, expands the company’s generic drug portfolio. Icatibant Injection is supplied as a prefilled, single-use syringe that is self-administered subcutaneously at the patient’s home or doctor’s office. In conjunction with launching its first specialty IV drug in the U.S., Fresenius Kabi is also launching KabiCare in the U.S., a comprehensive patient support program with case managers, co-pay assistance programs, injection training, and a patient assistance program.

December 01, 2020Fresenius Kabi

Brief News
Fresenius Helios reporting figures on intensive care occupancy

Fresenius Helios has started publishing daily figures on the occupancy rate for intensive care beds in its 86 German hospitals. The website of each hospital will report the number of COVID-19 patients in the hospital’s regular and intensive care wards. It will also publish figures from the Robert Koch Institute, Germany’s national health agency, on the number of new infections in the surrounding region. Helios’ goal is to increase transparency and facilitate a data-based assessment of the pandemic at the local level. Helios Germany currently has a total of 1,300 intensive care beds across the country and could add an additional 1,000 on short notice, in the event of a sharp increase in COVID-19 hospitalizations.

November 02, 2020Fresenius Helios
Fresenius continues to demonstrate resilience amid the COVID-19 pandemic: FY/20 guidance confirmed given accelerated earnings growth in Q3

October 29, 2020Fresenius

Fresenius announces changes to Supervisory Board

October 13, 2020Fresenius
Brief News
Fresenius Helios expands reporting on quality standards

As part of its reporting on quality standards, Fresenius Helios is publishing data on the length of patient stays, patient security and antibiotic use in the company’s German hospitals for the first time. Data from every Helios hospital is compiled in a total of 46 quality categories, including the frequency of surgical interventions and their results, and then published annually. The comparing of different hospitals’ statistics through the Quality Medicine Initiative yields specific, concrete improvements that can be implemented in day-to-day hospital operations. The initiative, which was jointly founded by Fresenius Helios, now includes more than 400 hospitals in Germany and Switzerland.

October 09, 2020Fresenius Helios

Brief News
Fresenius Kabi launches its first RFID smart-labeled product in the U.S.

Diprivan® (Propofol) injection, an anesthetic, is the company’s first smart-labeled product with radio frequency identification (RFID) technology and the 20 mL vial is now available in this enhanced presentation in the U.S. The smart label enables hospitals to automatically identify, locate and manage their inventory. Fresenius Kabi expects to introduce numerous other products with RFID technology in the coming year.

October 08, 2020Fresenius Kabi
Brief News
Fresenius Helios enters healthcare agreement with hotel operator in Spain

Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, has signed an agreement with Vincci Hotels to offer health careto guests in all accommodations in Spain. The service includes 24/7 medical assistance, either by video call, in person or by a doctor’s visit in the hotel, if necessary. This service is offered in several languages to meet the demands from international guests.

October 07, 2020Fresenius Helios

Fresenius successfully places bonds with a volume of one billion euros

September 21, 2020Fresenius
Brief News
2021 DRG inflator for German hospitals set at 2.53%

The price increase for hospital services in Germany has been set at 2.53% for 2021. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

September 14, 2020Fresenius Helios

Brief News
Fresenius Helios publishes study on intensive care COVID-19 patients

Fresenius Helios has published initial results from a study of all COVID-19 patients admitted to Helios hospitals in Germany that has been conducted since the start of the pandemic: Two of every three COVID-19 patents in intensive care in Germany require mechanical ventilation. One-third of ventilated intensive care patients die, compared with one-quarter of non-ventilated intensive care patients. This shows that the clinical course of COVID-19 patients in Germany is as poor as in countries hit harder by the pandemic such as Italy, France, the United Kingdom and Belgium. Helios, supported by the Brandenburg Medical School, started in February to collect and analyze data on COVID-19 patents treated in the Helios’ 86 German hospitals. These and additional findings that Helios makes from the study are expected to help in the development of a treatment for the virus.

August 25, 2020Fresenius Helios
Fresenius acquires Malteser hospitals in German state of North Rhine-Westphalia

August 20, 2020Fresenius Helios

Brief News
Fresenius Kabi introduces RFID Smart Labels for Medications in the U.S.

Beginning in Q4 2020, Fresenius Kabi will introduce smartlabels with radio frequency identification (RFID) technology for medications frequently used in the operating room in the U.S. The smart label enables hospitals to automatically identify, locate and manage their inventory. The first products in the smartlabel portfolio are anesthesia and analgesia products in prefilled syringes and vials.

August 18, 2020Fresenius Kabi

Disclaimer All News

Library

All Financial Reports

Follow us

The Health Care Group

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contacts

Visit us